Citius Oncology (CTOR) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
XBiotech (XBIT) has outperformed Citius Oncology (CTOR) over the past year, losing 24.1% versus a loss of 55.4%. Citius Oncology is the larger company by market cap ($53.2 million vs $52.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | XBIT |
|---|---|---|
| Share price | $0.5035 | $1.73 |
| Market cap | $53.25M | $52.74M |
| 1-day change | -10.95% | +2.98% |
| YTD return | -49.65% | -27.62% |
| 1-year return | -55.44% | -24.12% |
| 5-year return | — | -86.48% |
| Forward P/E | — | 13.31 |
| EPS (TTM) | $-0.48 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-24.76M | $-45.54M |
| 52-week high | $1.83 | $2.73 |
| 52-week low | $0.491 | $1.61 |
| Distance from 52-week high | -72.49% | -36.63% |
| Analyst consensus | none | — |
| Avg. price target upside | +694.44% | — |
| Average volume | 114.02K | 64.77K |
| Shares outstanding | 105.76M | 30.49M |
| Employees | — | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XBIT has outperformed CTOR by 31.3 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
CTOR vs XBIT FAQ
Which is bigger, Citius Oncology or XBiotech?
Citius Oncology (CTOR) is larger, with a market capitalization of $53.25M compared with $52.74M for XBiotech (XBIT).
Which stock has performed better over the past year, CTOR or XBIT?
XBIT returned -24.12% over the past 12 months, compared with -55.44% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.